Navigation Links
PAREXEL Appoints Charles A. Stevens as Vice President/General Manager of Health Policy and Strategic Reimbursement and Strengthens Capabilities
Date:12/10/2007

BOSTON, Dec. 10 /PRNewswire-FirstCall/ -- PAREXEL International (Nasdaq: PRXL) has appointed Charles A. Stevens as Vice President and General Manager of Health Policy and Strategic Reimbursement Services, a unit based in the Washington, D.C. area. Mr. Stevens leads a team of experts dedicated to helping PAREXEL's clients provide solutions to ensure patients have access to the medicines and therapies they require. His responsibilities include managing reimbursement service and patient assistance programs. Mr. Stevens oversees the Company's reimbursement strategy consulting practice, which is focused on helping clients navigate complexities of the ever changing healthcare payment system.

"As the biopharmaceutical industry undergoes market changes impacted by healthcare reform, new regulations, and changes in the area of reimbursement, we are meeting those needs with expanded capabilities," said Kurt Brykman, President of PAREXEL Consulting and Medical Communications Services at PAREXEL International. "We expect that the in-depth expertise and leadership Mr. Stevens brings to PAREXEL will further strengthen our ability to provide an increasing role in helping our clients to realize success in the area of reimbursement."

"I look forward to contributing my experience to helping our clients adopt the necessary strategies and transform their business models in order to provide optimal patient access to therapies," said Charles Stevens, Vice President and General Manager of Health Policy and Strategic Reimbursement Services, PAREXEL. "It is critical in this environment that biopharmaceutical and medical device companies demonstrate product value in new ways and develop reimbursement strategies early in a product
'/>"/>

SOURCE PAREXEL International
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. PAREXEL International to Present at Thomas Weisel Partners Healthcare Conference
2. Parexel Consulting Strengthens Good Manufacturing Practice Capabilities in Europe
3. PAREXEL International Completes Acquisition of APEX International Clinical Research Co., Ltd.
4. PAREXEL International Updates Financial Guidance in Conjunction with the Acquisition of APEX International Clinical Research Co., Ltd. and Other Factors
5. PAREXEL Announces Date of First Quarter Fiscal Year 2008 Earnings Release and Conference Call
6. PAREXEL Reports First Quarter Fiscal Year 2008 Financial Results
7. BioVex Appoints Dr. Thaddeus Pullano as VP, Quality Assurance
8. Codexis Appoints Singapore Laboratories Managing Director
9. Emisphere Technologies, Inc. Appoints Paul Lubetkin as Vice President and General Counsel
10. Nektar Therapeutics Appoints Tim Harkness as Chief Financial Officer
11. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/24/2009)...ntly approved the Promega PowerPlex 16 HS System f...ing DNA records for the National DNA Index System....) -- The FBI recently approved the Promega PowerP...ticipating in, or generating DNA records for, the ...ontains more than seven million profiles and has a...
(Date:11/24/2009)...PRNewswire-FirstCall/ -- Shire plc (LSE: SHP,NASD...al company, today,announced that it has submitted ...cerase alfa, the company,s enzyme replacement ther...cher disease. This is the third marketing,applicat..., with previous,submissions in the United States a...
(Date:11/24/2009)...ber 24 Health Robotics today annou...re with a group of selected,investors. This recent... the,name Health Robotics Canada, Inc. and will ma...oom of the Future concept, which includes the,revo...OFT(TM), and OMM(TM).,Health Robotics Canada Inc. ...
(Date:11/24/2009)...wswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI)... the 21st Annual Piper Jaffray Health Care Confere...9, at the New York Palace Hotel. ,, CTI will ...rn Time in Holmes 1 (4th Floor). A live audio webc...w.celltherapeutics.com , and it will also be avail...
Breaking Biology Technology:NDIS Approval of Promega PowerPlex Kit Clears Path for More DNA Profiles to be Added to U.S. Database 2Shire Submits European Marketing Authorization Application (MAA) for velaglucerase alfa for the Treatment of Type 1 Gaucher Disease 2Shire Submits European Marketing Authorization Application (MAA) for velaglucerase alfa for the Treatment of Type 1 Gaucher Disease 3Shire Submits European Marketing Authorization Application (MAA) for velaglucerase alfa for the Treatment of Type 1 Gaucher Disease 4Health Robotics Continues its Global Expansion With December 09 ASHP's Launch of Joint Venture in Canada 2Health Robotics Continues its Global Expansion With December 09 ASHP's Launch of Joint Venture in Canada 3
... to 2008 Lineup; Looks to Build Upon 2007 ... Dec. 20 Underscoring its continued commitment,to...reast cancer, the Avon,Foundation today announced ... the first time in Avon Walk history, the series w...ild upon the momentum of a record-breaking,2007 Av...
...ites Recently Initiated To Support Ongoing ...Expected in 2008 from Seven Ongoing or Planned Cli...ajor Disease Indications-, -Revenues Plus Cash On... Advance Programs as Planned-,...ls, Inc. (Nasdaq: PPHM ), a clinical stage biopha...
...nces for Potential Co-Development Opportunity in ...OUTH SAN FRANCISCO, Calif., Dec. 20 ,Exelixis, Inc...mitted a,comprehensive data report for IND candida...istol- Myers Squibb Company now has until the end ...e if it will select the compound for,further devel...
Other Biology Technology:Avon Foundation Announces 2008 Avon Walk for Breast Cancer Schedule 2Avon Foundation Announces 2008 Avon Walk for Breast Cancer Schedule 3Peregrine Pharmaceuticals Remains on Track to Advance its Three Lead Clinical Programs in 2008 2Peregrine Pharmaceuticals Remains on Track to Advance its Three Lead Clinical Programs in 2008 3Peregrine Pharmaceuticals Remains on Track to Advance its Three Lead Clinical Programs in 2008 4Peregrine Pharmaceuticals Remains on Track to Advance its Three Lead Clinical Programs in 2008 5Exelixis Submits XL139 Diligence Report to Bristol-Myers Squibb 2Exelixis Submits XL139 Diligence Report to Bristol-Myers Squibb 3Exelixis Submits XL139 Diligence Report to Bristol-Myers Squibb 4
(Date:11/24/2009)...y named 12 new grant recipients for 2009. The awar...rk across a broad spectrum of lupus research. All ...otential to drive scientific discovery to ultimate... systemic lupus. , The 2009 grants go to both ne...ion and include interdisciplinary and highly promi...
(Date:11/24/2009)...dical Toxicology (ACMT) have signed an agreement t...f Medical Toxicology (JMT), the official journal ...iously published by the University of Pennsylvania...an international, peer-reviewed journal, is dedica...al toxicology. The quarterly journal focuses on t...
(Date:11/24/2009).... , The presence of increased body fat, and ... in the blood, hinders the loss and maintenance of...e University of Navarra conducted by Estbaliz Goye.... , The project, entitled "A nutrigenetic and nu...y weight and inflammation," examines how the indiv...
Breaking Biology News(10 mins):Lupus Research Institute announces 2009 novel research grants 2Lupus Research Institute announces 2009 novel research grants 3Springer and the American College of Medical Toxicology to work together 2It can be predicted the reaction obese patients will have to a diet 2AMERIGROUP Foundation Honors Warehouse of Hope Founder Craig Parson as a Healthy Hero 53505 1AMERIGROUP Foundation Honors Warehouse of Hope Founder Craig Parson as a Healthy Hero 53505 2New Study Shows That Pharmacogenomics Could Benefit Patients Spur Investment in Innovation 53501 1New Study Shows That Pharmacogenomics Could Benefit Patients Spur Investment in Innovation 53501 2New Study Shows That Pharmacogenomics Could Benefit Patients Spur Investment in Innovation 53501 3New Analysis 3A Women of Low Socio Economic Status Face Unique Challenges Related to Smoking Smoking Ban Policies 53498 1New Analysis 3A Women of Low Socio Economic Status Face Unique Challenges Related to Smoking Smoking Ban Policies 53498 2New Analysis 3A Women of Low Socio Economic Status Face Unique Challenges Related to Smoking Smoking Ban Policies 53498 3New Analysis 3A Women of Low Socio Economic Status Face Unique Challenges Related to Smoking Smoking Ban Policies 53498 4New Analysis 3A Women of Low Socio Economic Status Face Unique Challenges Related to Smoking Smoking Ban Policies 53498 5
...g Quarterly Review of Biology, biologists from Bin...stinct types of laughter ?laughter which is stimul... strategic. , "Laughter that occurs during everyd...s and humorless conversation is now being studied,...he unstated issue is whether such laughter is simi...
...tudy in Science , More than 100 scientists from A...g the genome of the mouse in a joint study lasting... completely overturned geneticists, traditional as...igious journal Science on 2nd September. The gener...ammals is much more complex than was hitherto supp...
...oration Ecology finds that in coastal Louisiana, o...re self-sustaining, and are additionally attractiv...ntial for long-term growth, and contribute to over...ae move in groups and water-borne chemicals stimul...ble to maintain themselves as new recruits settle ...
Other Biology News:Mouse genome much more complex than expected 2
Rabbit Anti-OCT6 Polyclonal Antibody, Unconjugated from Abcam
Rabbit Anti-Human ABCD4 Polyclonal Antibody, Unconjugated from Atlas Antibodies
... Oligonucleotide) Genome Set and MEEBO (Mouse Exon...tain a collection of open source oligo probes, lar...allowing interrogation of thousands of genes. Deve... Stanford University and UCSF, the sets enable the...
Rabbit Anti-Human XPC Polyclonal Antibody, Unconjugated from Abcam
Biology Products: